M1 Kliniken AG (ISIN DE000A0STSQ8) has cancelled the treasury shares acquired under its share buyback programme and reduced its share capital accordingly.
On 25 March 2026, the Management Board resolved, with the approval of the Supervisory Board granted on 26 March 2026 and on the basis of the authorisation by the Annual General Meeting of 17 July 2024, to reduce the Company's share capital by EUR 1,088,289 from EUR 19,643,403 to EUR 18,555,114. The capital reduction became effective upon registration in the commercial register of the Local Court of Charlottenburg (HRB 107637 B) on 26 May 2026.
At today's balance sheet meeting, the Supervisory Board of M1 Kliniken AG (ISIN: DE000A0STSQ8) approved the annual financial statements and the consolidated financial statements of the Company for the 2025 financial year, as submitted by the Management Board, in accordance with §§ 171, 172 AktG. The annual financial statements are thereby adopted pursuant to § 172 AktG.
The Supervisory Board and the Management Board today resolved to propose to the Annual General Meeting a dividend of EUR 1.20 per dividend-bearing share.
The 2025 Annual Report of M1 Kliniken AG is expected to be published on 20 May 2026.
M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.
The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.
M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.
With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.
We use cookies on our website.Some of them are essential, while others help us to improve this website and your experience.
Technically necessary tools that enable essential services and basic functions, including identity verification, service continuity and site security. This option cannot be denied.
Schützt vor Cross-Site-Request-Forgery Angriffen.
Speichert die aktuelle PHP-Session.
Third-party content, e.g. stock widgets, are blocked by default. If third-party cookies are accepted, access to this content no longer requires manual consent.
We use the TradingView to display stock charts. This provider uses additional cookies to analyze its services.
By using this website, you consent to the use of cookies. You can find detailed information on the use of cookies on this website in the data protection declaration.
Menu
